In the first-line setting, the use of the anti-PD1 pembrolizumab was shown to be non-inferior to the platinum-based chemotherapy in patients with HER2-negative, PD-L1 positive tumors (i.e., Combined Positive Score [CPS] equal or higher than 1, intended as the PD-L1 positive fraction of tumor and/or immune-cell), in the KEYNOTE-062 trial [91]. This evidence concerns the gene CD274 and neoplasm.